



1st Edition

# M58

## Methods for the Identification of Cultured Microorganisms Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry

This guideline includes performance, reporting, and quality assurance recommendations for the identification of cultured microorganisms by medical laboratory professionals using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Recommendations for end-user verification and workflow integration are also included.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the *CLSI Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@cls.org](mailto:standard@cls.org)

M58, 1st ed.

April 2017

---

## Methods for the Identification of Cultured Microorganisms Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry

John A. Branda, MD  
Thomas R. Fritsche, MD, PhD  
Carey-Ann Burnham, PhD, D(ABMM)  
Susan Butler-Wu, PhD, D(ABMM)  
Christopher Doern, PhD, D(ABMM)  
Kirk M. Doing, PhD, D(ABMM)  
Daniel Fedorko, PhD  
Timothy S. Frana, DVM, MS, MPH, PhD  
John M. Gawoski, MD  
Christine Ginocchio, PhD, MT(ASCP)  
Camille Hamula, PhD, D(ABMM)  
Kevin Hazen, PhD

Katalin Kiss, PhD, PMP  
Julianne Kus, MSc, PHD, FCCM  
Lisa Mingle, PhD  
Michael Perry, MS, MS Ed  
David H. Pincus, MS, RM/SM(NRCM), SM(ASCP)  
Yvonne Shea, MS  
Laura Smoot, PhD  
Wayne F. Wang, MD, PhD  
Markita Weaver, MHA  
Nancy L. Wengenack, PhD, D(ABMM)  
Karla I. Ziegelmann-Fjeld, PhD

### Abstract

Clinical and Laboratory Standards Institute guideline M58—*Methods for the Identification of Cultured Microorganisms Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry* provides guidance to the end user for adopting matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the medical laboratory setting. Included are procedures and guidelines for preparing and analyzing cultured patient isolates, interpreting and reporting results, and troubleshooting. Best practices are described for ensuring quality and safety, and guidelines are provided for the initial introduction of MALDI-TOF MS into an existing laboratory, including method verification, training development and competence assessment programs, and operational considerations.

Clinical and Laboratory Standards Institute (CLSI). *Methods for the Identification of Cultured Microorganisms Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry*. 1st ed. CLSI guideline M58 (ISBN 1-56238-816-9 [Print]; ISBN 1-56238-817-7 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2017.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If you or your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



M58, 1st ed.

Copyright ©2017 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Methods for the Identification of Cultured Microorganisms Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry*. 1st ed. CLSI guideline M58. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.

ISBN 1-56238-816-9 (Print)  
ISBN 1-56238-817-7 (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

Volume 37, Number 6

## Committee Membership

### Consensus Council

**Carl D. Mottram, RRT, RPFT,**  
**FAARC**  
**Chairholder**  
**Mayo Clinic**  
**USA**

J. Rex Astles, PhD, FACB, DABCC  
Centers for Disease Control and  
Prevention  
USA

Lucia M. Berte, MA, MT(ASCP)SBB,  
DLM, CQA(ASQ), CMQ/OE  
Laboratories Made Better!  
USA

Karen W. Dyer, MT(ASCP), DLM  
Centers for Medicare & Medicaid  
Services  
USA

Dennis J. Ernst, MT(ASCP),  
NCPT(NCCT)  
Center for Phlebotomy Education  
USA

Thomas R. Fritsche, MD, PhD, FCAP,  
FIDSA  
Marshfield Clinic  
USA

Mary Lou Gantzer, PhD, FACB  
BioCore Diagnostics  
USA

Loralie J. Langman, PhD  
Mayo Clinic  
USA

Ross J. Molinaro, PhD,  
MLS(ASCP)CM, DABCC, FACB  
Siemens Healthcare Diagnostics, Inc.  
USA

Joseph Passarelli  
Roche Diagnostics Corporation  
USA

Andrew Quintenz  
Bio-Rad Laboratories, Inc.  
USA

Robert Rej, PhD  
New York State Department of  
Health – Wadsworth Center  
USA

Zivana Tezak, PhD  
FDA Center for Devices and  
Radiological Health  
USA

### Document Development Committee on Methods for the Identification of Cultured Microorganisms Using MALDI-TOF

**John A. Branda, MD**  
**Chairholder**  
**Massachusetts General Hospital**  
**USA**

**Thomas R. Fritsche, MD, PhD**  
**Vice-Chairholder**  
**Marshfield Clinic**  
**USA**

**Carey-Ann Burnham, PhD,**  
**D(ABMM)**  
**Committee Secretary**  
**Washington University School of**  
**Medicine**  
**USA**

Christopher Doern, PhD, D(ABMM)  
Virginia Commonwealth Medical  
Center  
USA

Kirk M. Doing, PhD, D(ABMM)  
Centura Health, Centura Laboratory  
Services  
USA

Timothy S. Frana, DVM, MS, MPH,  
PhD  
Iowa State University  
USA

Julianne Kus, MSc, PhD, FCCM  
Public Health Ontario  
Canada

Lisa Mingle, PhD  
New York State Department of Health  
USA

Yvonne Shea, MS  
FDA Center for Devices and  
Radiological Health  
USA

Markita Weaver, MHA  
MALDI Biotyper Americas  
USA

Nancy L. Wengenack, PhD, D(ABMM)  
Mayo Clinic  
USA

### Staff

Clinical and Laboratory Standards  
Institute  
USA

Marcy Hackenbrack, MCM, M(ASCP)  
*Project Manager*

Megan L. Tertel, MA, ELS  
*Editorial Manager*

Laura Martin  
*Editor*

Michael A. Russell, MA  
*Editor*

M58, 1st ed.

### Acknowledgment for the Expert Panel on Microbiology

CLSI, the Consensus Council, and the Document Development Committee on Methods for the Identification of Cultured Microorganisms Using MALDI-TOF gratefully acknowledge the Expert Panel on Microbiology for serving as technical advisors and subject matter experts during the development of this guideline:

**Richard B. Thomson, Jr., PhD,  
D(ABMM), FAAM  
Chairholder  
Evanston Hospital, NorthShore  
University Health System  
USA**

**Mary Jane Ferraro, PhD, MPH  
Vice-Chairholder  
Massachusetts General Hospital  
USA**

Lynette Y. Berkeley, PhD, MT(ASCP)  
FDA Center for Drug Evaluation and  
Research  
USA

Carey-Ann Burnham, PhD, D(ABMM)  
Washington University School of  
Medicine  
USA

German Esparza, BSc  
Proasecal LTD  
Colombia

Mark G. Papich, DVM, MS  
College of Veterinary Medicine, North  
Carolina State University  
USA

Jean B. Patel, PhD, D(ABMM)  
Centers for Disease Control and  
Prevention  
USA

David H. Pincus, MS,  
RM/SM(NRCM), SM(ASCP)  
bioMérieux, Inc.  
USA

Audrey N. Schuetz, MD, MPH,  
D(ABMM)  
Mayo Clinic  
USA

Ribhi M. Shawar, PhD, D(ABMM)  
FDA Center for Devices and  
Radiological Health  
USA

Barbara L. Zimmer, PhD  
Beckman Coulter - West  
Sacramento  
USA

### Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Methods for the Identification of Cultured Microorganisms Using MALDI-TOF gratefully acknowledge the following volunteers for their important contributions to the development of this guideline:

Susan Butler-Wu, PhD, D(ABMM)  
LAC/USC Medical Center  
USA

Daniel Fedorko, PhD  
FDA Center for Devices and  
Radiologic Health  
USA

Mark Fisher, PhD, D(ABMM)  
University of Utah and ARUP  
Laboratories  
USA

John M. Gawoski, MD  
Lahey Hospital & Medical Center  
USA

Christine Ginocchio, PhD,  
MT(ASCP)  
bioMérieux, Inc.  
USA

Jerry L. Harris, MD  
College of American Pathologists  
USA

Camille Hamula, PhD, D(ABMM)  
Mt. Sinai Hospital – New York  
USA

Kevin Hazen, PhD  
Duke University Medical Center  
USA

Katalin Kiss, PhD, PMP  
American Type Culture Collection  
USA

David R. Peaper, MD, PhD  
Yale New Haven Hospital  
USA

Michael Perry, MS, MS Ed  
New York State Department of  
Health – Wadsworth Center  
USA

David H. Pincus, MS,  
RM/SM(NRCM), SM(ASCP)  
bioMérieux, Inc.  
USA

Mary Ann Silvius  
Thermo Fisher Scientific, Remel  
USA

Laura Smoot, PhD  
Beckman Coulter - West  
Sacramento  
USA

Wayne F. Wang, MD, PhD  
Grady Health System  
USA

Karla I. Ziegelmann-Fjeld, PhD  
Microbiologies, Inc.  
USA

## Contents

|   |     |
|---|-----|
| Abstract.....   | i   |
| Committee Membership.....   | iii |
| Foreword.....   | vii |
| Chapter 1: Introduction.....  | 1   |
| 1.1 Scope.....  | 1   |
| 1.2 Background.....   | 2   |
| 1.3 Standard Precautions.....   | 5   |
| 1.4 Terminology.....  | 5   |
| Chapter 2: The MALDI-TOF MS Process.....  | 9   |
| 2.1 Selecting Isolates for MALDI-TOF MS Analysis.....   | 11  |
| 2.2 Preparing Isolates for MALDI-TOF MS Analysis.....   | 13  |
| 2.3 Interpreting Results, Troubleshooting, and Performing Supplemental Testing.....                               | 23  |
| 2.4 Reporting Guidelines.....   | 31  |
| Chapter 3: Quality System Essentials for Microbial Identification Using MALDI-TOF MS.....                         | 37  |
| 3.1 Facilities and Safety.....  | 37  |
| 3.2 Personnel: Guidelines for Training and Competence Assessment.....   | 40  |
| 3.3 Process Management: Integrating MALDI-TOF MS Into an Existing Diagnostic Laboratory Operation.....            | 42  |
| 3.4 Process Management: Guidelines for End-User Verification of Microorganism Identification by MALDI-TOF MS..... | 47  |
| 3.5 Process Management: Ensuring Quality in MALDI-TOF MS Testing.....   | 51  |
| Chapter 4: Conclusion.....  | 56  |
| Chapter 5: Supplemental Information.....  | 56  |
| References.....   | 57  |
| Additional Resources.....   | 62  |
| Appendix A. Example Quick Reference Guide for MALDI-TOF MS Identification Testing of Microorganisms.....          | 63  |
| Appendix B. Common MALDI-TOF MS Reagents/Consumables and General Use Guidelines.....                              | 64  |
| Appendix C. MALDI-TOF MS Training Checklist Example.....  | 66  |
| Appendix D. Technical Training and Competence Assessment Form Example.....  | 67  |
| Appendix E. Validating Novel or Customized Spectral Databases.....  | 70  |
| Appendix F. Example Verification Protocols.....   | 72  |
| The Quality Management System Approach.....   | 78  |
| Related CLSI Reference Materials.....   | 79  |

This is a preview of "CLSI M58-Ed1". [Click here to purchase the full version from the ANSI store.](#)

M58, 1st ed.



## Foreword

The application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to cultured microorganism identification represents a paradigm shift in diagnostic microbiology practices. Compared with conventional phenotypic and biochemical methods, MALDI-TOF MS is frequently faster and more accurate. It has expanded the capabilities of many microbiology laboratories by providing for identification of organisms within certain groups (eg, anaerobes, coagulase-negative staphylococci) that could not otherwise be identified reliably or practically using conventional methods. For larger diagnostic laboratories, the technology reduces the need for referral laboratory testing for identifying agents such as mycobacteria and fungi.

**NOTE:** The content of this guideline is supported by the CLSI consensus process, and does not necessarily reflect the views of any single individual or organization.

## Key Words

Mass spectrometry, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, microbial identification

This is a preview of "CLSI M58-Ed1". [Click here to purchase the full version from the ANSI store.](#)

M58, 1st ed.

# Methods for the Identification of Cultured Microorganisms Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry

## Chapter 1: Introduction

This chapter includes:

- Guideline's scope and applicable exclusions
- Background information pertinent to the guideline's content
- Standard precautions information
- "Note on Terminology" that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the guideline
- Abbreviations and acronyms used in the guideline

### 1.1 Scope

This guideline establishes best practices for applying and integrating matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) technology into the diagnostic microbiology laboratory. It presents preexamination considerations, such as selecting appropriate isolates for analysis and isolate preparation from solid or liquid media, and postexamination activities, such as results interpretation, indications for supplemental testing, and results reporting. Practical recommendations are provided for integrating MALDI-TOF MS into an existing traditional laboratory operation; for establishing QC procedures, safety procedures, and a competence assessment program; and for designing a method verification protocol.

The intended users of this guideline are microbiologists in private, academic, and commercial diagnostic laboratory settings, including public health laboratories and veterinary diagnostic laboratories.

This guideline:

- Is not intended for use in the research setting
- Is not intended to provide guidance pertaining to identifying microorganisms directly from patient specimens (before culture)
- Does not cover antimicrobial susceptibility testing (AST) using MALDI-TOF MS
  - Although several studies have demonstrated that MALDI-TOF MS can be adapted for this purpose, its utility in a diagnostic laboratory setting remains undefined, and the methods are still in development.